New York State Common Retirement Fund Has $16.76 Million Holdings in Baxter International Inc. (NYSE:BAX)

New York State Common Retirement Fund decreased its position in Baxter International Inc. (NYSE:BAX - Free Report) by 14.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 441,500 shares of the medical instruments supplier's stock after selling 74,877 shares during the period. New York State Common Retirement Fund owned about 0.09% of Baxter International worth $16,764,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BAX. Bank of New York Mellon Corp lifted its position in shares of Baxter International by 73.2% in the second quarter. Bank of New York Mellon Corp now owns 6,772,533 shares of the medical instruments supplier's stock worth $226,541,000 after purchasing an additional 2,862,626 shares in the last quarter. LSV Asset Management purchased a new stake in Baxter International in the 2nd quarter worth approximately $140,296,000. Shapiro Capital Management LLC boosted its stake in shares of Baxter International by 19.7% during the 2nd quarter. Shapiro Capital Management LLC now owns 3,285,048 shares of the medical instruments supplier's stock valued at $109,885,000 after buying an additional 541,575 shares during the period. Thompson Siegel & Walmsley LLC purchased a new position in shares of Baxter International during the 2nd quarter valued at $67,263,000. Finally, Coho Partners Ltd. acquired a new position in shares of Baxter International in the third quarter worth $57,229,000. 90.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Morgan Stanley lowered Baxter International from an "equal weight" rating to an "underweight" rating and dropped their target price for the stock from $39.00 to $30.00 in a research report on Monday, July 15th. Citigroup raised their target price on Baxter International from $38.00 to $40.00 and gave the company a "neutral" rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Baxter International from a "hold" rating to a "buy" rating in a research note on Tuesday, October 22nd. Wells Fargo & Company decreased their target price on Baxter International from $44.00 to $40.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 7th. Finally, The Goldman Sachs Group increased their price target on shares of Baxter International from $36.00 to $40.00 and gave the company a "neutral" rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Baxter International presently has an average rating of "Hold" and a consensus price target of $41.20.

Baxter International Price Performance

Shares of BAX stock traded up $0.02 during trading hours on Wednesday, hitting $36.12. The company had a trading volume of 3,696,343 shares, compared to its average volume of 4,028,963. Baxter International Inc. has a 12 month low of $32.48 and a 12 month high of $44.01. The company has a debt-to-equity ratio of 1.35, a quick ratio of 0.91 and a current ratio of 1.40. The firm's fifty day moving average is $37.53 and its 200 day moving average is $36.16. The firm has a market capitalization of $18.43 billion, a price-to-earnings ratio of 7.43, a PEG ratio of 1.21 and a beta of 0.60.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.02. Baxter International had a return on equity of 18.06% and a net margin of 16.51%. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.75 billion. During the same period in the prior year, the company posted $0.55 earnings per share. The business's revenue for the quarter was up 2.8% compared to the same quarter last year. On average, sell-side analysts predict that Baxter International Inc. will post 2.96 EPS for the current fiscal year.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.